[go: up one dir, main page]

WO2002000613A3 - Inhibitors of hepatitis b virus infection - Google Patents

Inhibitors of hepatitis b virus infection Download PDF

Info

Publication number
WO2002000613A3
WO2002000613A3 PCT/EP2001/007260 EP0107260W WO0200613A3 WO 2002000613 A3 WO2002000613 A3 WO 2002000613A3 EP 0107260 W EP0107260 W EP 0107260W WO 0200613 A3 WO0200613 A3 WO 0200613A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
inhibitors
infections
hepatitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007260
Other languages
French (fr)
Other versions
WO2002000613A2 (en
Inventor
Dorian Bevec
Sabine Obert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axxima Pharmaceuticals AG
Original Assignee
Axxima Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxima Pharmaceuticals AG filed Critical Axxima Pharmaceuticals AG
Priority to AU2001269092A priority Critical patent/AU2001269092A1/en
Publication of WO2002000613A2 publication Critical patent/WO2002000613A2/en
Publication of WO2002000613A3 publication Critical patent/WO2002000613A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to inhibitors of Hepatitis B Virus (HBV). A class of guanyl hydrazones are disclosed to be powerful inhibitors of HBV infection. Such compounds are useful for the treatment of HBV infection, in particular chronic HBV infection and for the treatment of opportunistic infections and diseases caused by HBV infections. Furthermore, the present invention discloses pharmaceutical compositions useful for prophylaxis and/or treatment of HBV infections, including opportunistic infections, and diseases caused by HBV infections.
PCT/EP2001/007260 2000-06-27 2001-06-26 Inhibitors of hepatitis b virus infection Ceased WO2002000613A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001269092A AU2001269092A1 (en) 2000-06-27 2001-06-26 Inhibitors of hepatitis b virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21455600P 2000-06-27 2000-06-27
US60/214,556 2000-06-27

Publications (2)

Publication Number Publication Date
WO2002000613A2 WO2002000613A2 (en) 2002-01-03
WO2002000613A3 true WO2002000613A3 (en) 2002-11-07

Family

ID=22799534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007260 Ceased WO2002000613A2 (en) 2000-06-27 2001-06-26 Inhibitors of hepatitis b virus infection

Country Status (2)

Country Link
AU (1) AU2001269092A1 (en)
WO (1) WO2002000613A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
US7001924B2 (en) 2001-09-21 2006-02-21 Message Pharmaceuticals Inhibitors of RNase P proteins as antibacterial compounds
CN100536853C (en) 2002-09-13 2009-09-09 艾登尼科斯（开曼）有限公司 beta-L-2' -deoxynucleosides for the treatment of resistant HBV strains and combination therapy
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
CA2577156C (en) * 2004-08-17 2013-11-26 Cytokine Pharmasciences, Inc. Guanylhydrazone compounds, compositions, methods of making and using
US7795314B2 (en) 2005-06-01 2010-09-14 Cytokine Pharmasciences, Inc. Protective role of semapimod in necrotizing enterocolitis
EP2155675B1 (en) 2007-06-12 2014-02-19 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
KR20150090219A (en) * 2012-12-06 2015-08-05 바루크 에스. 블럼버그 인스티튜트 Functionalized Benzamide Derivatives as Antiviral Agents against HBV Infection
CN113134002B (en) * 2021-04-26 2023-12-19 北京慧宝源生物技术股份有限公司 Use of clevudine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923398A (en) * 1960-08-09 1963-04-10 Vismara Francesco Spa Diphenyl mono-and bis-formyl guanylhydrazones
US3560557A (en) * 1965-11-19 1971-02-02 Ciba Geigy Corp Diphenyl-ureas,-thioureas,-guanidines and -parabanic acids
US5689563A (en) * 1993-06-29 1997-11-18 Motorola, Inc. Method and apparatus for efficient real-time authentication and encryption in a communication system
WO1998020868A1 (en) * 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones useful for treating diseases associated with t cell activation
WO1998030583A1 (en) * 1997-01-08 1998-07-16 The Picower Institute For Medical Research Complexes and combinations of fetuin with therapeutic agents
US5854289A (en) * 1994-01-21 1998-12-29 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
WO2001056553A2 (en) * 2000-02-02 2001-08-09 Axxima Pharmaceuticals Ag Pharmaceutically active aromatic guanylhydrazones
WO2002011715A2 (en) * 2000-08-07 2002-02-14 Melacure Therapeutics Ab The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923398A (en) * 1960-08-09 1963-04-10 Vismara Francesco Spa Diphenyl mono-and bis-formyl guanylhydrazones
US3560557A (en) * 1965-11-19 1971-02-02 Ciba Geigy Corp Diphenyl-ureas,-thioureas,-guanidines and -parabanic acids
US5689563A (en) * 1993-06-29 1997-11-18 Motorola, Inc. Method and apparatus for efficient real-time authentication and encryption in a communication system
US5854289A (en) * 1994-01-21 1998-12-29 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
WO1998020868A1 (en) * 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones useful for treating diseases associated with t cell activation
WO1998030583A1 (en) * 1997-01-08 1998-07-16 The Picower Institute For Medical Research Complexes and combinations of fetuin with therapeutic agents
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
WO2001056553A2 (en) * 2000-02-02 2001-08-09 Axxima Pharmaceuticals Ag Pharmaceutically active aromatic guanylhydrazones
WO2002011715A2 (en) * 2000-08-07 2002-02-14 Melacure Therapeutics Ab The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAVALLINI G ET AL: "ANTIBACTERIAL AGENTS. SOME NEW GUANYLHYDRAZONE DERIVATIVES", JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 4, no. 1, 1 July 1961 (1961-07-01), pages 177 - 182, XP001021572 *
CERAMI, CARLA ET AL: "High-performance liquid chromatographic method for guanylhydrazone compounds", J. CHROMATOGR., B: BIOMED. APPL. (1996), 675(1), 71-5, XP002206329 *
COHEN P S ET AL: "The critical role of p38 MAP kinase in T cell HIV -1 replication.", MOLECULAR MEDICINE, vol. 3, no. 5, May 1997 (1997-05-01), pages 339 - 346, XP001018447 *
KORYTNYK, W. ET AL: "Guanylhydrazones with potential antileukemic activity. 2. Synthesis and structure-activity relationships of analogs of 4,4'-diacetyl-N,N'-diphenylurea bis(guanylhydrazone)", J. MED. CHEM. (1978), 21(6), 507-13, XP002206328 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression
US9127278B2 (en) 2011-04-21 2015-09-08 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Also Published As

Publication number Publication date
WO2002000613A2 (en) 2002-01-03
AU2001269092A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
WO2002048157A3 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
EP2431379A3 (en) HCV inhibitors
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2001074768A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
WO2002008198A3 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
IL215891A (en) Hepatitis c virus serine protease inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of hepatitis c virus infections
WO2004032827A3 (en) Hepatitis c virus inhibitors
WO2006039668A3 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2004046159A8 (en) Antiviral nucleoside derivatives
WO2007008657A3 (en) Hepatitis c virus inhibitors
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
NO20052130L (en) Strong inhibitor of HCV serine protease
WO2003093290A8 (en) Nucleoside derivatives for treating hepatitis c virus infection
GB0321003D0 (en) Compounds, compositions and uses
TW200505944A (en) Crystalline phases of a potent HCV inhibitor
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
UA83046C2 (en) Hepatitis c inhibitor compounds, pharmaceutical composition based thereon
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
MX9603909A (en) Sulphonamide derivatives as aspartyl protease inhibitors.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP